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Abstract
Background:  Cathepsin B is thought to play a central role in intrapancreatic trypsinogen
activation and the onset of pancreatitis. A recent investigation of the cathepsin B mediated
activability of wildtype trypsinogen and their mutations N29I, N29T and R122H, which are
associated to hereditary pancreatitis, revealed no differences. This action seems to be restricted
to the K23-I24 peptide bond, which is the trypsinogen activation bond. Here we investigated the
influence of the mutations D22G and K23R of the trypsinogen activation peptide on the cleavability
by cathepsin B.
Methods: To investigate the functional impact of the TAP mutations on cathepsin B mediated
cleavage of the trypsinogen activating K23-I24 bond, the corresponding peptides pWT,
APFDDDDKIVGG; pD22G, APFDDDGKIVGG; and pK23R, APFDDDDRIVGG were digested
with cathepsin B for 30 min at pH 3.8 and 5.0, and the fragments were analysed by high-
performance liquid chromatography.
Results: Without cathepsin B, less than 1 % of the peptides were hydrolysed. After a 30-minute
digestion with cathepsin B at pH 5, 96% of pWT, 48% of pK23R, but only 2.4% of pD22G were
hydrolysed. At pH 3.8, the cathepsin B cleavage of pWT and pK23R was less than at pH 5, whereas
the cleavage of pD22G was completely inhibited
Conclusions: Cathepsin B mediated trypsinogen activation seems not to be a crucial pathogenic
step in hereditary pancreatitis patients with the trypsinogen mutations D22G and K23R.
Background
In families with hereditary pancreatitis, a cationic
trypsinogen mutation is a predominant risk factor for the
manifestation of chronic pancreatitis [1]. Almost all dis-
ease-associated mutations are located within the active en-
zyme ( [http://www.uni-leipzig.de/pancreasmutation]);
three other gained interest, as they change the amino acid
sequence of the trypsinogen activation peptide (TAP), but
not the active trypsin molecule. In detail, the A16V muta-
tion alters the cleavage bond A15-A16 of the signal pep-
tide [2]. The D22G variant destroys the highly conserved
tetraaspartic group of TAP [3], whereas K23R directly af-
fects the trypsinogen activation bond K23-I24 [4] (table
1). As reported earlier, D22G and K23R facilitate the hy-
drolysis of the K23-I24 bond by active trypsin, what could
lead to pancreatitis by enhanced trypsinogen autoactiva-
tion [3].
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The lysosomal cysteine protease cathepsin B is thought to
play a central role in intrapancreatic trypsinogen activa-
tion and the onset of pancreatitis. It activates human
trypsinogen in vitro [5] and was found to be redistributed
to a zymogen-granule enriched subcellular compartment
during the early course of experimental pancreatitis [6].
Studies with cathepsin B deficient mice presented evi-
dence, that the premature and intracellular activation of
trypsinogen largely depends on the presence of cathepsin
B [7]. A recent study showed that cathepsin B is abundant-
ly present in the secretory compartment of the healthy hu-
man pancreas and is secreted together with trypsinogen
and active trypsin into the pancreatic juice of patients with
chronic pancreatitis [8]. The authors conclude, that
trypsinogen and cathepsin B could potentially interact.
This interaction may be modified by pancreatitis associat-
ed trypsinogen mutations. The investigation of the wild
type trypsinogen molecule and three distinct mutants
(i.e., N29I, N29T and R122H) found that cathepsin B me-
diated trypsinogen activation was not influenced by the
respective mutants [8].
The studies by Kukor et al. imply, that the proteolytic
cleavage of trypsinogen by cathepsin B is restricted to the
K23-I24 trypsinogen activation peptide bond in the TAP
[8]. In contrast to the mutations N29I, N29T and R122H,
which are located away from this cleavage site, trypsino-
gen mutations affecting the K23-I24 bond could poten-
tially affect the cathepsin B action on trypsinogen
activation. The aim of this study was to evaluate the cathe-
psin B mediated cleavage of the K23-I24 bond in the pres-
ence of the pancreatitis associated TAP mutations D22G
and K23R.
Materials and Methods
Unless otherwise indicated, all reagents were obtained
from Sigma-Aldrich (Deisenhofen/Germany). Human liv-
er cathepsin B (Sigma-Aldrich, catalog number C8571, en-
zymatic activity 3,930 units/mg protein) was used in a
final concentration of 0.14 ng/µl. The oligopeptides
shown in table 1 were commercially synthesized (MWG
Biotech, Ebersberg, Germany) and purified by high-per-
formance liquid chromatography (HPLC), and their mo-
lecular masses were verified by mass spectrometry. To
investigate the functional impact of the TAP mutations on
cathepsin B mediated cleavage of the trypsinogen activat-
ing K23-I24 bond, the corresponding peptides pWT,
pD22G and pK23R were digested with cathepsin B. These
dodecapeptides are homologous to the N-terminal part of
wild type human cationic trypsinogen and the pancreatitis
associated mutations D22G and K23R and include the ac-
tivation peptide cleavage site (table 1).
pH 3.8 has been previously used in the activation of hu-
man trypsinogen [8]. The concentration of cathepsin B in
lysosomes is high (about 1 mM) [9] and pH 5 mimics the
approximate intralysosomal pH, the putative cellular
compartment of trypsinogen activation in acute pancrea-
titis [10–14]. Therefore, all experiments have been carried
out at both pH 3.8 and 5.0.
A solution of 2 mg dodecapeptide /mL of buffer (40 mM
sodium acetate + 40 mM cysteine) with pH 3.8 and pH
5.0, was used [5]. Cathepsin B was added, and the mixture
was incubated for 30 min at 37°C. As control, the peptides
were incubated without addition of cathepsin B. The sam-
ples were then centrifuged using the Microcon centrifugal
filter device YM-10 (catalogue no. 42406, Millipore, Bed-
ford, MA) to remove cathepsin B from peptides or hydro-
lytic fragments. Next, 100 µl of the eluates was then
separated by HPLC. After HPLC separation, the undigest-
ed peptides were eluted at a retention time of approxi-
mately 14 minutes. The N-terminal octapeptide was
eluted after 11.6 minutes, and the residual C-terminal
tetrapeptide was detected after 8.6 minutes. The method
has been described in detail in reference [3].
Rates of hydrolysis were determined by integration of the
respective area under each peak, and the digestion rates
were indicated as percentages of initial dodecapeptide
concentration.
Results and Discussion
Without cathepsin B, less than 1 % of the peptides was hy-
drolysed. After a 30-minute digestion with cathepsin B at
pH 5, 96% of pWT, 48% of pK23R, but only 2.4% of
pD22G were hydrolysed. At pH 3.8, the cathepsin B cleav-
age of pWT and pK23R was less than at pH 5, whereas the
cleavage of pD22G was completely inhibited (figure 1).
In contrast to pancreatitis associated trypsin mutations,
pancreatitis associated TAP mutations potentially prevent
the hydrolytic activity of cathepsin B. The respective cleav-
age of the K23-I24 bond was reduced by 50% by the K23R
mutation and largely inhibited by the D22G mutation.
Table 1: Sequences of synthetic peptides in the 1-letter-code; un-
derlined letters represent the mutated amino acids. The tryptic 
cutting site K23-I24 of the peptides are marked with dashes. 
pWT, wild type peptide; pD22G, peptide D22G; pK23R, peptide 
K23R.
peptide amino acid sequence
pWT APFDDDDK-IVGG
pD22G APFDDDGK-IVGG
pK23R APFDDDDK-IVGGBMC Gastroenterology 2002, 2 http://www.biomedcentral.com/1471-230X/2/16
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This indicates a high control of cathepsin B action on
trypsinogen activation by the amino acid structure of TAP
and highlights the particular functional importance of the
D22 residue within the tetraaspartic group D19-D20-
D21-D22.
An experimental setup using mutant dodecapeptides but
not trypsinogen molecules might be questioned, as the
structural organization of the N-terminal part of native
trypsinogen is different from that of the synthetic oli-
gopeptide. However, the recombinant expression of hu-
man trypsinogen is difficult and has been carried out by
only two groups worldwide, with partially conflicting re-
sults due to different analytical conditions [8,15]. Crystal-
lographic studies of the trypsinogen-to-trypsin conversion
revealed that TAP can move freely in space and lacks a dis-
tinct secondary and tertiary structure [16]. In the past, the
activation process of trypsinogen was analysed in numer-
ous studies using oligopeptides [17] and the method used
here has been proven to be highly reproducible [3].
The investigated TAP mutations have been discovered, as
their carriers have chronic pancreatitis. With respect to
that clinical picture it is highly unlikely, that a reduced ac-
tivation of trypsinogen by cathepsin B provokes pancrea-
titis, but favors the role of trypsinogen autoactivation by
active trypsin. Our data support the generally accepted hy-
pothesis, that pancreatitis is caused by increased intrapan-
creatic trypsin activity. In contrast to this attractive
hypothesis of gain-of-function trypsins in hereditary pan-
creatitis, recent in vitro studies have challenged these as-
sumptions and suggested that a loss of trypsin function
could impair the inactivation of other (more pancreato-
toxic?) digestive enzymes [18,19]. These new insights sug-
gest, that structural alterations, which impair the function
of trypsin, could eliminate a protective mechanism rather
than triggering an aggressive mechanism in initiating pan-
creatitis. However, our investigations on the cleavability
of the trypsinogen activation bond bond by active trypsin
[3] and cathepsin B provide further evidence, that autoac-
tivation rather than cathepsin B mediated trypsinogen ac-
tivation is the key pathogenic event in the development of
hereditary pancreatitis in D22G and K23R-carriers.
In summary, two effects have been shown for the
trypsinogen mutants D22G and K23R: (I) The trypsin me-
diated TAP-cleavage is facilitated. This could overwhelm
the pancreatic protease-antiprotease-equilibrium and
may lead to pancreatitis [3]. (II) The cathepsin B mediated
TAP-cleavage is reduced. The resulting impaired cathepsin
B mediated trypsinogen activation seems not be a pancre-
atitis promoting pathogenic step.
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